Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Immix Biopharma, Inc. - Common Stock
(NQ:
IMMX
)
5.230
-0.050 (-0.95%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 31, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Immix Biopharma, Inc. - Common Stock
< Previous
1
2
3
4
Next >
Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
December 09, 2025
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
December 07, 2025
From
Immix Biopharma, Inc.
Via
GlobeNewswire
At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
December 07, 2025
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch
November 12, 2025
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025
November 03, 2025
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
October 14, 2025
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting
October 06, 2025
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference
October 01, 2025
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2
September 18, 2025
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors
September 11, 2025
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang
September 08, 2025
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma to Present at the Stifel 2025 Healthcare Conference
August 25, 2025
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Announces Other Serious Diseases Strategy
August 06, 2025
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion
July 11, 2025
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis
July 07, 2025
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Attends FDA CEO Forum in Washington DC
June 06, 2025
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
June 03, 2025
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
May 23, 2025
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
May 22, 2025
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis
May 21, 2025
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025
April 23, 2025
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis
February 10, 2025
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T
January 07, 2025
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis
December 19, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis
December 16, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024
December 10, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media
December 09, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients
November 25, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2
October 02, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board
September 19, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
